CN111150749A - Use of caramel treats extract for preparing composition for improving gene expression and beautifying skin appearance - Google Patents
Use of caramel treats extract for preparing composition for improving gene expression and beautifying skin appearance Download PDFInfo
- Publication number
- CN111150749A CN111150749A CN201910448804.0A CN201910448804A CN111150749A CN 111150749 A CN111150749 A CN 111150749A CN 201910448804 A CN201910448804 A CN 201910448804A CN 111150749 A CN111150749 A CN 111150749A
- Authority
- CN
- China
- Prior art keywords
- gene
- skin
- caramel
- extract
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 235000013736 caramel Nutrition 0.000 title claims abstract description 91
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 230000014509 gene expression Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000037075 skin appearance Effects 0.000 title abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 108010076876 Keratins Proteins 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 108060008539 Transglutaminase Proteins 0.000 claims abstract description 17
- 230000037303 wrinkles Effects 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 108010063290 Aquaporins Proteins 0.000 claims abstract description 8
- 101710128038 Hyaluronan synthase Proteins 0.000 claims abstract description 6
- 108010017544 Glucosylceramidase Proteins 0.000 claims abstract description 5
- 241001164374 Calyx Species 0.000 claims description 32
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 12
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 101150071538 AQP gene Proteins 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 claims description 9
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims description 9
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 claims description 9
- 102000011782 Keratins Human genes 0.000 claims description 9
- 101710088660 Filaggrin Proteins 0.000 claims description 8
- 102100028314 Filaggrin Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 7
- 102000004363 Aquaporin 3 Human genes 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 102000010637 Aquaporins Human genes 0.000 claims description 6
- 108010070514 Keratin-1 Proteins 0.000 claims description 6
- 108010065038 Keratin-10 Proteins 0.000 claims description 6
- 108010066321 Keratin-14 Proteins 0.000 claims description 6
- 102000003601 transglutaminase Human genes 0.000 claims description 5
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 claims description 3
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 claims description 3
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 claims description 3
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 claims description 3
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 claims description 3
- 101700032040 SMAD1 Proteins 0.000 claims description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 108010058734 transglutaminase 1 Proteins 0.000 claims description 3
- 102000004547 Glucosylceramidase Human genes 0.000 claims 2
- 230000008774 maternal effect Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 95
- 239000003795 chemical substances by application Substances 0.000 description 25
- 210000002510 keratinocyte Anatomy 0.000 description 20
- 101150063233 FLG gene Proteins 0.000 description 17
- 101150028412 GBA gene Proteins 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000003020 moisturizing effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 101150106024 Aqp3 gene Proteins 0.000 description 8
- 101150089672 HAS3 gene Proteins 0.000 description 8
- 101150027313 Has2 gene Proteins 0.000 description 8
- 101150058971 KRT10 gene Proteins 0.000 description 8
- 101150040052 KRT14 gene Proteins 0.000 description 8
- 101150056422 Krt1 gene Proteins 0.000 description 8
- 101150042171 Smad1 gene Proteins 0.000 description 8
- 101150039702 TGM1 gene Proteins 0.000 description 8
- 230000002087 whitening effect Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 3
- 229920000832 Cutin Polymers 0.000 description 3
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229930007503 menthone Natural products 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 244000099487 Labisia pumila Species 0.000 description 2
- 241000245063 Primula Species 0.000 description 2
- 235000000497 Primula Nutrition 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 244000132069 Carica monoica Species 0.000 description 1
- 235000014649 Carica monoica Nutrition 0.000 description 1
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 description 1
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- -1 serums Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to application of a caramel treats extract, in particular to application of the caramel treats extract in preparing a composition for improving gene expression and beautifying skin appearance. The caramel treats extract is obtained by extracting caramel treats with a solvent of water, alcohol or an alcohol-water mixture. The Qihua pedicel Ma extract is used for improving the expression levels of transglutaminase genes, keratin genes, aquaporin genes, keratin microfilament genes, parent anti-Dpp homolog genes, glucocerebrosidase genes and hyaluronic acid synthase genes, and can effectively reduce skin wrinkles, skin melanin and skin moisture loss.
Description
Technical Field
The invention relates to application of a caramel treats extract, in particular to application of the caramel treats extract in preparing a composition for improving gene expression and beautifying skin appearance.
Background
The epidermis is the outermost layer of the skin, which is composed of the stratum corneum, the stratum granulosum, the stratum spinosum and the stratum basale in that order from the outside to the inside, and is mainly formed by the continuous upward differentiation of undifferentiated cylindrical keratinocytes in the stratum basale, which is called keratinization. The water content in the keratinocyte is high, the keratinocyte gradually becomes flat as the cells are metabolized and differentiated upwards, and the cell nucleus and the cell apparatus begin to degenerate and shrink, and dead cells without the cell nucleus and the cell organelle are formed in the horny layer. The main function of the epidermis layer is to retain water in the skin and form a skin barrier to protect against various external injuries, wherein the outermost layer of the epidermis layer is composed of a weakly acidic sebum membrane and a cuticle layer in a brick wall structure, and the barrier can lock water and grease in the skin, resist the invasion of germs on the surface of the skin, resist the injury of external foreign matters, ultraviolet light and the like, and has very important protection effect on the human body.
Although the horny cells in the epidermis are dead cells, the horny cells are mainly keratin (keratin), which can absorb water to keep the skin moist, and the horny cells can also secrete substances such as hyaluronic acid as intercellular substance to maintain the structural integrity of the epidermis skin barrier, so as to prevent the skin water loss and form complete protection. When the skin is exposed to an environment with excessive cooling or overheating and is irradiated with ultraviolet light and the like, the keratinocytes cannot maintain normal metabolic cycle, the water retention capacity of the skin is also reduced, and the skin epidermal barrier is damaged, so that the skin becomes rough, dry, desquamation, fragile, easily stimulated and sensitive to reddening, and therefore, the health and water retention capacity of the stratum corneum are very important for resisting the invasion of external injuries.
In addition, in recent years, in order to meet the demand of people for whitening skin and reducing speckles, various whitening products for inhibiting melanin formation or lightening speckles have been developed on the market, however, in order to achieve special effects, these products are added with too many carcinogenic chemicals or environmental hormones, so that consumers use ingredients which can harm skin and affect health under unknown conditions.
In view of the above, in order to solve the problem that the skin becomes fragile and sensitive due to the damaged keratinocytes and the decreased water retention capacity, there is a need to develop a comprehensive skin care composition that can effectively make the keratinocytes secrete more moisturizing factors, maintain the arrangement of the keratinocytes, maintain the structural integrity of the horny layer, improve the barrier function of the skin, and simultaneously satisfy the skin whitening requirements.
Disclosure of Invention
Accordingly, an object of the present invention is to provide a use of a caramel calyx ma extract for preparing a composition for increasing expression level of Transglutaminase (TGM) gene, Keratin (KRT) gene, Aquaporin (AQP) gene, Filaggrin (FLG) gene, motheragainst Dpp homolog (SMAD) gene, Glucocerebroside (GBA) gene, and/or Hyaluronic Acid Synthase (HASs) gene, wherein the caramel calyx ma extract is obtained by extracting a caramel calyx with a solvent, which is water, alcohol, or an alcohol-water mixture; wherein the composition is a pharmaceutical, a food or a nutraceutical.
It is another object of the invention to provide a use of a caramel calyx ma extract for the preparation of a composition for beautifying the appearance of skin, wherein the caramel calyx ma extract is obtained by extracting a caramel calyx ma with a solvent, the solvent being water, alcohol, or an alcohol-water mixture; wherein the composition is a pharmaceutical, a food or a nutraceutical.
In one embodiment of the invention, the weight ratio of the solvent to the caramel calyx ma is 5-20: 1-5, and the extraction temperature is 50-100 ℃.
In yet another embodiment of the present invention, the TGM gene is Transglutaminase 1 (TGM 1) gene; the KRT gene comprises Keratin 1(Keratin1, KRT1) gene, Keratin10 (Keratin10, KRT10) gene and Keratin14 (Keratin14, KRT14) gene; the AQP gene is Aquaporin3 (AQP 3) gene; the SMAD gene is the parent Dpp homolog (Mothers against decapentaplegic homolog 1, SMAD1) gene; and the HAS gene comprises a Hyaluronan synthase 2(Hyaluronan synthase 2, HAS2) gene and a Hyaluronan synthase 3(Hyaluronan synthase 3, HAS3) gene, and the concentration of the caramel calyx extract is at least 0.125 mg/mL.
In another embodiment of the invention, the aesthetic skin appearance is reduced skin wrinkles, reduced skin melanin, and/or reduced skin moisture loss, and the concentration of caramel treats extract is at least 0.125 mg/mL.
The caramel calyx extract can effectively improve the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, can effectively reduce skin wrinkles, reduce skin melanin and reduce skin moisture loss, and HAS the effects of improving the expression of skin TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene, and resisting wrinkles, whitening and moisturizing skin, so that more moisturizing factors are formed on the skin, the structural integrity of stratum corneum is maintained, and the barrier function of the skin is improved. Therefore, the caramel treats extract of the invention can be used for preparing a composition for improving the expression level of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene of skin and beautifying the appearance of skin, and the composition is a medicine, a food or a health-care product and can be administered to an individual by oral administration, skin smearing and the like.
The following examples are presented to illustrate the present invention and are not to be construed as limiting the scope of the invention, which is intended to be limited only by the appended claims.
Drawings
FIG. 1 is a bar graph showing the effect of caramel treats extract of the present invention on increasing the expression level of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene;
*p＜0.05；**p＜0.01；***p＜0.001；
fig. 2 is a bar graph of the effect of caramel calyx ma extract of the present invention in reducing skin wrinkles;
*p＜0.05；
fig. 3 is a bar graph of the effect of caramel calyx ma extract of the present invention in reducing skin melanin;
*p＜0.05；#p＜0.05；
fig. 4 is a bar graph of the effect of caramel calyx ma extract of the present invention in reducing skin moisture loss;
*p＜0.05。
Detailed Description
Definition of
As used herein, the numerical values are approximations and all numerical data are reported to be within the 20 percent range, preferably within the 10 percent range, and most preferably within the 5 percent range.
Statistical analysis was performed using Excel software. Data are presented as mean ± Standard Deviation (SD), and differences between individual data are analyzed by student's t-test (student's t-test).
According to the invention, caramel treats (Labisia Pumila) is a perennial herb of the primula family (primula) known under the english name Kacip Fatimah, native to malaysia, translated from the marvin. Caramel calyx is grown in a dwarf, has a single or few branched stems and hairy roots, has long round leaves with fine hair below, and has a length of about 20-40 cm, brown inflorescence and a length of about 5-6 cm. Caramel calyx Ma can be used for relieving dysmenorrhea and treating flatulence.
As used herein, the term "caramel calyx extract" means that the caramel calyx is extracted with a solvent at a ratio of 1-5: 5-20(w/w) for a specific time and temperature.
As used herein, the term "beautifying the appearance of the skin" means preventing, slowing down the aging phenomenon of the appearance of human skin, such as: for example: the generation of wrinkles and loss of elasticity; to improve the fair and shiny appearance of human skin, for example: reducing the content and the generation of skin melanin, and the like; and/or to increase human skin moisturization and moisture content, such as: reduce the water loss of the skin, and the like. The degree of evaluation to achieve this will be determined by a number of factors known to those skilled in the art, such as the general state of the consumer, age, sex, and the like.
According to the present invention, the drug may be manufactured in a dosage form suitable for parenteral (parenteral) or topical (topologic) administration using techniques well known to those skilled in the art, including, but not limited to: injections (injection) [ e.g., sterile aqueous solution (sterile aqueous solution) or dispersion (dispersion) ], sterile powders (sterile powder), external preparations (external preparation), and the like.
According to the present invention, the pharmaceutical may further comprise a pharmaceutically acceptable carrier (pharmaceutically acceptable carrier) which is widely used in pharmaceutical manufacturing technology. For example, the pharmaceutically acceptable carrier may comprise one or more agents selected from the group consisting of: solvents (solvent), buffers (buffer), emulsifiers (emulsifying), suspending agents (suspending agent), disintegrating agents (disintegrant), disintegrating agents (disintegrating agent), dispersing agents (dispersing agent), binding agents (binding agent), excipients (excipient), stabilizers (stabilizing agent), chelating agents (chelating agent), diluents (diluent), gelling agents (gelling agent), preservatives (preserving), wetting agents (wetting agent), lubricants (lubricating), absorption delaying agents (solubilizing agent), liposomes (liposome) and the like. The selection and amounts of such agents are within the skill and routine skill of those skilled in the art.
According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of: water, normal saline (normal saline), Phosphate Buffered Saline (PBS), aqueous alcohol-containing solutions (aqueous solution linking alcohol), and combinations thereof.
According to the invention, the medicament may be administered by a parenteral route (parenteral routes) selected from the group consisting of: subcutaneous injection (subecanal injection), intradermal injection (intraepithelial injection), and intralesional injection (intralesion).
According to the present invention, pharmaceuticals can be manufactured into an external preparation (external preparation) suitable for topical application to the skin using techniques well known to those skilled in the art, including, but not limited to: creams (lotions), liniments (liniments), powders (powders), aerosols (aerogels), sprays (sprays), emulsions (positions), serums (serums), pastes (pastes), foams (foams), drops (drops), suspensions (suspensions), ointments (salves), and bandages (bandages).
According to the present invention, the external preparation is prepared by mixing the medicine of the present invention with a base (base) as well known to those skilled in the art.
According to the invention, the substrate may comprise one or more additives (additives) selected from the following group: water, alcohols, glycols, hydrocarbons such as petroleum jelly and white petrolatum]Wax (wax) [ such as paraffin (paraffin) and yellow wax (yelloowwax)]Preserving agents (preserving agents), antioxidants (antioxidants), surfactants (surfactants), absorption enhancers (absorption enhancers), stabilisers (stabilizing agents), gelling agents (gelling agents) [ such as
Microcrystalline cellulose (microcrystalline cellulose) and carboxymethyl cellulose (carboxymethyl cellulose)]Active agents (active agents), humectants (humectants), odor absorbers (odor absorbers), fragrances (fragrances), pH adjusting agents (pH adjusting agents), chelating agents (chelating agents)Emulsifiers (emulisifiers), occlusive agents (occlusive agents), softeners (emulsifiers), thickeners (thinners), solubilizing agents (solvating agents), penetration enhancers (penetration enhancers), anti-irritants (anti-irritants), colorants (colorants), and propellants (propellants). The selection and amounts of such additives are within the skill and routine skill of those skilled in the art.
According to the present invention, the care product may further comprise an acceptable adjuvant (acceptable adjuvant) which is widely used in the art of care product manufacture. For example, the acceptable adjuvant may comprise one or more agents selected from the group consisting of: solvents, gelling agents, active agents, preservatives, antioxidants, screening agents, chelating agents, surfactants, colouring agents, thickening agents, fillers, fragrances and odour absorbers. The selection and amounts of such agents are within the skill and routine skill of those skilled in the art.
In accordance with the present invention, the cosmetic may be manufactured in a form suitable for skin care (skincare) or makeup (makeup) using techniques well known to those skilled in the art, including, but not limited to: aqueous solutions (aqueous solutions), aqueous-alcoholic solutions (aqueous-alcoholic solutions) or oily solutions (oil solutions), emulsions in the form of oil-in-water type, water-in-oil type or compound type, gels, ointments, creams, masks (masks), patches, wipes, powders, aerosols, sprays, lotions, serums, pastes, foams, dispersions, drops, mousses (mousses), sunblocks, lotions (toiletries), foundations (foundations), make-up removal products (make-up removal products), soaps (soaps), and other body cleansing products (body cleansing products).
In accordance with the present invention, the cosmetic may also be used in combination with one or more known active topical agents (extralute agents) selected from the following: whitening agents (whitening agents) [ such as retinoic acid (tretinoin), catechins (catechin), kojic acid, arbutin and vitamin C ], moisturizers, anti-inflammatory agents (anti-inflammatory agents), bactericides (bacteriodes), ultraviolet absorbers (ultraviolets), plant extracts [ such as aloe vera extract (aloe extract) ], skin nutrients (skin nutrients), anesthetics (anesthesics), anti-acne agents (anti-acne agents), antipruritics (antipruritics), analgesics (analgesics), anti-dermatitis agents (antipermatitis agents), anti-hyperkeratotic agents (anti-hypercholesterolitic agents), anti-dry skin agents (anti-dry skin agents), anti-perspirants (anti-perspirant agents), anti-aging agents (anti-aging agents), anti-wrinkle agents (anti-rinking agents), anti-seborrheic agents (anti-anerrheic agents), wound healing agents (wound-healing agents), corticosteroids (corticosteriods), and hormones (hormones). The selection and amounts of such agents for external use are within the skill and routine skill of those skilled in the art.
According to the present invention, the food product may be used as a food additive (food additive) to be added during the preparation of the raw material or during the preparation of the food by conventional methods, and formulated with any edible material into a food product for ingestion by humans and non-human animals.
According to the present invention, the types of food products include, but are not limited to: beverages (leafages), fermented foods (fermented foods), bakery products (bakery products), health foods (health foods) and dietary supplements (dietary supplements).
The invention provides a caramel calyx-shaped extract for preparing a preparation for improving TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene and beautifying skin appearance, wherein the caramel calyx-shaped extract is obtained by extracting caramel calyx-shaped with a solvent which is water, alcohol or alcohol-water mixture, and can be used for improving the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, and resisting wrinkle, whitening and moisturizing skin.
Meanwhile, the composition for improving the expression amount of the TGM gene, the KRT gene, the AQP gene, the FLG gene, the SMAD gene, the GBA gene and the HAS gene and beautifying the appearance of skin can also comprise an effective amount of caramel calyx extract and a pharmaceutically acceptable carrier, and the composition is a medicine, a food or a nutrient.
The detailed extraction method of caramel treats extract of the present invention, and the test of the caramel treats extract for regulating the expression level of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene in skin keratinocytes and the test for reducing skin wrinkles, skin melanin and skin moisture loss will be described in detail below, so as to confirm the effect of the caramel treats extract for improving the expression of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene, and reducing skin wrinkle, skin whitening and skin moisturizing.
Example 1 preparation of caramel treats extract according to the invention
In one embodiment of the present invention, the whole caramel treats is washed, the washed whole caramel treats is extracted by an extraction solvent which is water, alcohol or an alcohol-water mixture, preferably water, the caramel treats and the extraction solvent are mixed in a weight ratio of 1-5: 5-20, and the extraction is carried out in the solvent for 0.5-3 hours. After extraction, it was cooled to room temperature, and the crude extract was filtered through a 0.45-0.2 μm sieve to obtain a filtrate. Finally, the filtrate is concentrated under reduced pressure at 45-70 ℃ to obtain the caramel calyx ma extract of the present invention.
Example 2 Effect of caramel treats extract of the present invention on controlling expression levels of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene in keratinocytes
The invention uses human primary dermal keratinocytes (HPEK) to analyze the expression of the carica calyx extract in the expression of Transglutaminase 1 (TGM 1) gene, Keratin 1(Keratin1, KRT1) gene, Keratin10 (Keratin10, KRT10) gene, Keratin14 (Keratin14, KRT14) gene, Aquaporin 3(Aquaporin3, AQP3) gene, Filaggrin microfilament (Filaggrin, FLG) gene, parent Dagainst Dtheraai decapentaplegic homolog, SMAD) gene, Glucocerebrosidase (Glucocerebrosidase, GBA) gene, hyaluronic acid synthase 2 (Hyalsynthon synthase 2, Hyalkininonase 2) gene, and hyalon 3 (Hymenon 3) gene. The human primary skin keratinocytes were purchased from CELLnTEC (Switzerland) under the reference HPEK-50 and cultured in serum-free keratinocyte medium (Keratinocyte-SFM) (Gibco, Inc. # 10724-.
Human primary keratinocytes were divided into five groups: (1) control group containing only cell culture fluid for 24 hours of action (2) test group to which 0.25mg/mL of caramel treats extract of the invention is added for 6 hours of action (3) test group to which 0.125mg/mL of caramel treats extract of the invention is added for 6 hours of action, (4) test group to which 0.25mg/mL of caramel treats extract of the invention is added for 24 hours of action, and (5) test group to which 0.125mg/mL of caramel treats extract of the invention is added for 24 hours of action; wherein the caramel calyx extract of this example is extracted with water. Next, after the keratinocytes were collected in a cell lysate (RB buffer, available from Geanaid, Taiwan, China, Cat No. RBD300-DG), RNA in two groups of cells was collected using an RNA extraction reagent kit (available from Geneaid, Taiwan, China, Lot No. FC24015-G), and then used
III reverse transcriptase (purchased from Invitrogene, USA, No. 18080-051) 2000ng of extracted RNA was used as template and primers to generate the corresponding cDNA product of mRNA reverse transcription, followed by the use of ABI StepOneplusTMReal-Time PCR system (Thermo Fisher Scientific, USA), and KAPA SYBR FAST (Sigma, USA, number 38220000000) two sets of reverse transcription products were tested with the combination primers in Table I for quantitative Real-Time reverse transcription polymerase chain reaction (quantitative Real-Time reverse transcription polymerase chain reaction) under the conditions of 95 ℃ for 1 second, 60 ℃ for 20 seconds, and a total of 40 cycles. For quantifying the amount of the TGM1 gene, KRT1 gene, KRT10 gene,mRNA expression amounts of KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene, wherein the quantitative value is obtained by threshold cycle number (Ct), and the relative amount of mRNA of the target gene is derived from equation 2-ΔCtWhere Δ Ct ═ CtTarget gene-CtACTB(β -actin, beta-actin), and then using Excel software to perform unpaired single tail t-test to determine if the coefficient of variation is statistically significantly different (p value < 0.05;. p value < 0.01;. p value < 0.001).
TABLE I, QUANTITATIVE REAL-TIME COMBINED DIGENT FOR RETROPTIC POLYMERASE CHAIN REACTION
The results of the caramel calyx extract of the present invention for increasing the expression levels of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene are shown in fig. 1. Previous studies have shown that TGM can form strong bonds between the cell membrane and structural proteins of keratinocytes and increase the strength and stability of the epidermal layer; KRT forms keratin fibrils, while FLG helps keratin fibrils assemble into a strong network, providing strength and elasticity to the skin; AQP can increase the water permeability of keratinocyte to increase the water content of keratinocyte; SMAD is a signal-transmitting factor associated with regulation of collagen expression; GBA is involved in maintaining the integrity of the keratinous structure; HAS can promote the capability of keratinocyte to secrete hyaluronic acid, make the structure of the skin stratum corneum complete, improve the barrier function of the skin, and improve the water retention capacity of the skin, wherein the expression quantity of AQP genes and HAS genes, particularly HAS genes, can effectively enable the keratinocyte to secrete more moisturizing factors.
After the human primary keratinocyte is treated by the caramel calyx Ma extract, the expression level of TGM1 gene can be effectively increased to 2.7 times, the expression level of KRT1 gene can be increased to 4.4 times, the expression level of KRT10 gene can be increased to 1.1 times, the expression level of KRT14 gene can be increased to 1.2 times, the expression level of AQP3 gene can be increased to 1.7 times, the expression level of FLG gene can be increased to 1.2 times, the expression level of SMAD1 gene can be increased to 1.1 times, the expression level of GBA gene can be increased to 1.6 times, the expression level of HAS2 gene can be increased to 2.1 times, and the expression level of HAS3 gene can be increased to 1.6 times. The results show that the caramel treats extract can effectively improve the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, can enable skin cutin to secrete more moisturizing factors, and can maintain the arrangement of the cutin cells and the structural integrity of the cutin layer so as to improve the barrier function of the skin.
Example 3 efficacy of caramel treats extract of the present invention for reducing skin wrinkles
To confirm the efficacy of the caramel treats extract of the present invention in reducing skin wrinkles, first, a caramel treats mask to which 2% of the caramel treats extract of the present invention is added is prepared; and a mask not containing the caramel treats extract of the invention is used as a control group, wherein the essence components contained in the mask are water, menthone, hexanediol, 1, 3-butanediol, xanthan gum, a thickening agent and triethanolamine, and the caramel treats extract of the embodiment is extracted by water. Then, after 8 subjects were recruited, each subject was washed every morning and evening, the control mask and the mask containing the caramel calyx extract of the present invention were applied to the skin of the left and right half faces for 15 minutes, respectively, and then removed, absorption was promoted by applying a slight rubbing to the finger abdomen, skin texture detection was performed before and 4 weeks after use using a VISIA skin detector (CIS-visia.7 VISIA complex Analysis System, cantield scientific, usa, serial No. V71214), the facial skin was photographed using a high resolution monocular camera in combination with three light sources (light sources of full light wavelength, ultraviolet light and polarized wave region), and after obtaining a clear image file, texture Analysis was performed using professional software.
The results of the caramel treats extract of the present invention in reducing skin wrinkles are shown in fig. 2. After the mask containing the caramel treats extract is used, skin wrinkles are remarkably reduced by 20.8% compared with the mask before use; at the same time, up to 87.5% of subjects showed significant improvement after use; whereas the control group with caramel treats extract not containing the present invention was only reduced by 7.3%. This result shows that the caramel treats extract of the present invention is effective in reducing skin wrinkles, and has a significant anti-wrinkle effect on the skin.
Example 4 efficacy of caramel treats extract of the invention for reducing skin melanin
To confirm the efficacy of the caramel treats extract of the present invention in reducing skin melanin, first, a caramel treats mask to which 2% of the caramel treats extract of the present invention is added is prepared; and a mask not containing the caramel treats extract of the invention is used as a control group, wherein the essence components contained in the mask are water, menthone, hexanediol, 1, 3-butanediol, xanthan gum, a thickening agent and triethanolamine, and the caramel treats extract of the embodiment is extracted by water. Then, 8 subjects were recruited, each subject washed their face in the morning and evening, and the control mask and the mask containing the caramel calyx extract of the present invention were applied to the skin of the left and right half of the face for 15 minutes and removed, and the finger abdomens were slightly rubbed to promote absorption, and CK was applied before and 4 weeks after application
A dual MPA 580 multi-probe skin analyzer (CK electronic, Germany) is used for skin quality detection of skin melanin indexes, wherein the principle of spectrum absorption is utilized, and an MX18 probe is matched to measure the reflection quantity of color light (green light source: 568nm +/-3nm, red light source: 660nm +/-3nm and infrared light source: 880nm +/-10 nm) with specific wavelength related to melanin on human skin, and the absorption quantity of the melanin to the specific wavelength is utilized to define skin complexion and calculate the relative content of the melanin in the skin. The percentage of improvement after use is given as the percentage obtained before application, relative to the melanin value before application, which is 100%.
The results of the caramel treats extract of the invention in reducing skin melanin are shown in fig. 3. After the mask containing the caramel treats extract is used, the melanin index is obviously reduced by 3.6 percent compared with that before the mask is used, the melanin index is increased by 1.3 percent on the contrary by a control group, and the two have obvious difference; at the same time, up to 87.5% of subjects showed a significant improvement after using the mask containing the caramel treats extract of the present invention. The result shows that the caramel treats extract can effectively reduce the content of skin melanin and has remarkable skin whitening effect.
Example 5 efficacy of caramel treats extract of the invention for reducing skin moisture loss
To confirm the efficacy of the caramel treats extract in reducing skin moisture loss, firstly, a caramel treats mask added with 2% of the caramel treats extract is prepared; and a mask not containing the caramel treats extract of the invention is used as a control group, wherein the components of the essence contained in the mask are water, menthone, hexanediol, 1, 3-butanediol, xanthan gum, a thickening agent and triethanolamine, and the caramel treats extract of the embodiment is extracted by water. Then, 8 subjects were recruited, each subject washed their face in the morning and evening, and the control mask and the mask containing the caramel calyx extract of the present invention were applied to the skin of the left and right half of the face for 15 minutes and removed, and the finger abdomens were slightly rubbed to promote absorption, and CK was applied before and 4 weeks after application
A dual MPA 580 multi-probe skin analyzer (CK electronic, Germany) is used for skin quality detection of skin moisture loss (TEWL), wherein a cylindrical hollow probe with two open ends is used to form a relatively stable detection environment on the skin surface, water loss from the stratum corneum of the near epidermis (within about 1 cm) is measured through two groups of temperature and humidity sensors in the probe, and a water vapor pressure gradient formed by different temperatures and humidity of the upper and lower groups of sensors in the probe is substituted into Fick's law to calculate the TEWL value (unit is g/hm)2Representation). The TEWL value before use is 100 percent, and the percentage is the change after use relative to the percentage obtained before useGood percentage of the situation.
The results of the caramel calyx extract of the present invention in reducing skin moisture loss are shown in fig. 4. After the mask containing the caramel treats extract of the invention, the moisture loss was significantly reduced by 14.5% and the control by only 5.2% compared to before use. The result shows that the caramel treats extract can effectively reduce the moisture loss of the skin and has obvious skin moisturizing effect.
In conclusion, the caramel calyx extract of the invention can effectively improve the expression of the TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, can effectively reduce skin wrinkles, skin melanin and skin moisture loss, and HAS the effects of improving the expression of the TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene, and the effects of resisting wrinkles, whitening and moisturizing skin, so that more moisturizing factors are formed on the skin, the structure of the stratum corneum is maintained to be complete, and the skin barrier function is improved. Therefore, the caramel treats extract of the invention can be used for preparing a composition for improving the expression level of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene of skin and beautifying the appearance of skin, and the composition is a medicine, a food or a health-care product and can be administered to an individual by oral administration, skin smearing and the like.
Claims (13)
1. Use of a caramel calyx ma extract obtained by extracting caramel calyx ma with a solvent, wherein the solvent is water, alcohol, or an alcohol-water mixture, for the preparation of a composition for enhancing expression of Transglutaminase (TGM) gene, Keratin (KRT) gene, Aquaporin (AQP) gene, Filaggrin (FLG) gene, maternal anti-Dpp homolog (SMAD) gene, Glucocerebrosidase (GBA) gene, and/or Hyaluronic Acid Synthase (HAS) gene.
2. Use according to claim 1, characterized in that the TGM gene is the Transglutaminase 1 (TGM 1) gene.
3. The use according to claim 1, wherein the KRT gene comprises Keratin 1(Keratin1, KRT1) gene, Keratin10 (Keratin10, KRT10) gene and Keratin14 (Keratin14, KRT14) gene.
4. The use according to claim 1, wherein said AQP gene is the Aquaporin 3(Aquaporin3, AQP3) gene.
5. The use according to claim 1, wherein the SMAD gene is the maternal anti-Dpp homolog (mothergainst decapentaplegic homolog 1, SMAD1) gene.
6. The use according to claim 1, wherein the HAS gene comprises a Hyaluronan synthase 2(Hyaluronan synthase 2, HAS2) gene and a Hyaluronan synthase 3(Hyaluronan synthase 3, HAS3) gene.
7. Use according to claim 1, wherein the concentration of caramel calyx ma extract is at least 0.125 mg/mL.
8. Use of a caramel treats extract for the preparation of a composition for beautifying the appearance of skin, wherein the caramel treats extract is obtained by extracting caramel treats with a solvent, the solvent being water, alcohol, or an alcohol-water mixture.
9. Use according to claim 8, wherein the beautifying of the appearance of the skin is a reduction of skin wrinkles, a reduction of skin melanin and/or a reduction of skin moisture loss.
10. Use according to claim 8, wherein the concentration of caramel calyx ma extract is at least 0.125 mg/mL.
11. Use according to claim 1 or 8, wherein the weight ratio of the solvent to the caramel calyx ma is 5-20: 1-5.
12. Use according to claim 1 or 8, characterized in that the extraction temperature is 50-100 ℃.
13. The use according to claim 1 or 8, wherein the composition is a medicament, a food or a nutraceutical.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107139542 | 2018-11-07 | ||
| TW107139542A TWI776985B (en) | 2018-11-07 | 2018-11-07 | Use of labisia pumila extract for improving skin elasticity, strength or stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111150749A true CN111150749A (en) | 2020-05-15 |
Family
ID=70555772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910448804.0A Pending CN111150749A (en) | 2018-11-07 | 2019-05-27 | Use of caramel treats extract for preparing composition for improving gene expression and beautifying skin appearance |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111150749A (en) |
| TW (1) | TWI776985B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090113723A (en) * | 2008-04-28 | 2009-11-02 | 동국대학교 산학협력단 | A cosmetic composition, a pharmaceutical composition comprising extract or fermented product from labisia pumila |
-
2018
- 2018-11-07 TW TW107139542A patent/TWI776985B/en active
-
2019
- 2019-05-27 CN CN201910448804.0A patent/CN111150749A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090113723A (en) * | 2008-04-28 | 2009-11-02 | 동국대학교 산학협력단 | A cosmetic composition, a pharmaceutical composition comprising extract or fermented product from labisia pumila |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI776985B (en) | 2022-09-11 |
| TW202017581A (en) | 2020-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8709511B2 (en) | External preparation composition for skin comprising ginseng flower or ginseng seed extracts | |
| EP2370052B1 (en) | Novel sebum secretion inhibitory agent | |
| JP6387219B2 (en) | Skin external preparation composition containing tangeretin and EGCG | |
| CN108498408B (en) | Whitening essence | |
| KR20160043935A (en) | Anti-dandruff compositions, and methods of use thereof | |
| KR102315208B1 (en) | Cosmetic or dermatological use of a polygonum bistorta extract | |
| TW201420107A (en) | Extract of Phalaenopsis amabilis petals, and the preparation process and uses thereof | |
| CN112236201B (en) | Use of extract of rosewood (BIXA ORELLANA) | |
| KR101862039B1 (en) | A cosmetic composition containing spicule powder and natural complex extract stabilized in nanoliposome | |
| TWI729618B (en) | Use of phalaenopsis plant extract for anti-glycation and improving skin appearance | |
| TW201420128A (en) | Extract of Phalaenopsis amabilis embryo, and the preparation process and uses thereof | |
| KR101922637B1 (en) | Cosmetic composition for skin whitening and improving skin wrinkle comprising horse oil and Rumex acetosella L. extracts | |
| CN111150749A (en) | Use of caramel treats extract for preparing composition for improving gene expression and beautifying skin appearance | |
| TWI687237B (en) | Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin | |
| KR102333132B1 (en) | Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil | |
| JP5855949B2 (en) | Keratin production promoter, hair dye and nail polish | |
| JP6723979B2 (en) | Wrinkle improver | |
| TW202038903A (en) | Use of compound essential oil composition for regulating the gene expression level of mmp, mc1r, krt, tert, terc, and/or ogg1 | |
| CN111184822A (en) | Application of cogongrass rhizome fermentation product in improving gene expression quantity, promoting proliferation of collagen and elastin and improving oxidation resistance | |
| TWI788019B (en) | Use of chamaemelum nobile extract for manufacturing skincare composition | |
| KR20160000318A (en) | Cosmetic composition containing Fir tree oil | |
| KR102013164B1 (en) | Composition for improving skin | |
| TWI740096B (en) | Use of tussilago farfara extract for enhancing the gene expression of tgm, krt, aqp, flg, gba, and has | |
| JP2022543141A (en) | Novel cosmetic use of willow herb (Epilobium angustifolium) extract | |
| JP2024088811A (en) | Filaggrin mrna expression-promoting agents, hyaluronan synthase 3 mrna expression-promoting agents, moisturizers and external moisturizing compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200515 |